INTRAVENOUS (IV) IBUPROFEN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Intravenous (IV) Ibuprofen Market Size and Trends

Global intravenous (IV) ibuprofen market is estimated to be valued at USD 6.91 Bn in 2024 and is expected to reach USD 11.13 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7% from 2024 to 2031.

Discover market dynamics shaping the industry request sample copy

Global intravenous (IV) ibuprofen market is witnessing positive growth trends over the past few years. The market growth is driven by rising prevalence of pain disorders and increasing demand for analgesics. Intravenous ibuprofen is increasingly being used for treatment of mild to moderate pain associated with medical or surgical conditions. Its availability as a generics has further increased its adoption rate as compared to other intravenous pain drugs. Ongoing research activities to expand approved indications is expected to present new avenues for growth of the intravenous (IV) ibuprofen market during the forecast period.

Market Driver – Market Acceptance as Oral Medication Alternative

The use of intravenous (IV) ibuprofen as an alternative to traditional oral medications is increasingly gaining acceptance among healthcare providers and patients. Oral medications require patients to be conscious and mobile enough to swallow pills. However, intravenous delivery ensures that medication is administered directly into the bloodstream in its entirety, allowing it to take effect much faster for those unable to take oral medications due to severe pain, nausea, unconsciousness or other issues. With intravenous delivery, healthcare practitioners also have greater confidence that the full prescribed dose is being received by the patient. This is proving particularly valuable in clinical settings like surgery recovery rooms, emergency departments and intensive care units where rapid pain relief is a high priority. As hospitals and physicians witness benefits of more direct, reliable dosing with intravenous (IV) ibuprofen, its acceptance and utilization as a replacement for inconvenient oral pills is expected to grow.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Get instant access to report

With the ongoing opioid epidemic, there is significant focus on adoption of non-narcotic options for managing pain. In comparison to opioid painkillers, intravenous (IV) ibuprofen provides an appealing non-addictive alternative that carries less risk of side effects or potential for abuse. Regulators and medical organizations have also been promoting greater use of non-opioid therapies. As a result, healthcare providers and patients have become increasingly receptive to non-opioid options like intravenous (IV) ibuprofen. It addresses pain in a reliable, consistent manner without the medical and social risks tied to opioids. With sustained policy and clinical emphasis on curbing opioid prescriptions, the preference for effective non-opioid therapies is enhancing the attractiveness of intravenous ibuprofen. Many people view it as an important tool in improving post-procedure and post-surgery pain management while avoiding opioids whenever clinically appropriate. This makes intravenous (IV) ibuprofen well-positioned for stronger market growth.

To learn more about this report, request sample copy

Patent expiration of intravenous (IV) ibuprofen products is expected to face lower-cost generic competition, which can significantly impact the revenues of existing intravenous (IV) ibuprofen players. This may lead to loss of market share for branded products.

Market Opportunities – Increasing Number of Orthopedic Surgeries

There is an increasing number of orthopedic surgeries being conducted minimally invasively such as arthroscopic and endoscopic procedures. Such surgeries require intravenous anti-inflammatory drugs like ibuprofen for post-operative pain management. This rising trend can boost the demand for intravenous (IV) formulation of ibuprofen.

Discover high revenue pocket segments and roadmap to it: Get instant access to report

Indication segment is sub-segmented into pain management, fever, and others. Pain management segment is expected to hold 63.3% of the market share in 2024 due to the growing prevalence of chronic and acute pain worldwide. Ibuprofen provides effective relief from various types of pain, thus, making it the preferred choice among clinicians. Its anti-inflammatory and analgesic properties makes it highly effective in treating both moderate to severe pain arising from diverse conditions. A key driver of the segment is rising cases of postoperative pain following surgeries. As the volume and complexity of surgical procedures increases globally, the needs for optimized postoperative pain management increases. Ibuprofen infusion enables round the clock relief and improves recovery outcomes for patients. Its rapid onset of action and long-lasting effects through IV administration fulfils this need well. Allergen free property of ibuprofen facilitates its widespread adoption. It overcomes limitations of other nonsteroidal anti-inflammatory drugs which often cause intolerability. Overall, these multifaceted advantages have cemented ibuprofen infusion as a frontline choice in widespread pain indications fueling growth of the segment.

Insights, By Age Group: Rising pediatric patient volume boosts growth

Age Group segment is sub-segmented into pediatrics and adults. Pediatrics segment is expected to hold 54.4% of the market share in 2024. Effective pain relief remains a priority need in pediatrics managing conditions from surgeries to trauma. However, pain assessment can be challenging in children due to communication barriers. Ibuprofen excellently caters this underserved demographic. Its proven safety record, even in premature neonates, has increased acceptability replacing alternative analgesics. Ibuprofen formulation allows flexible dosing tailored to infants and young children's unique requirements. The rising incidence of appendicitis and similar painful infections also impacts its demand. Ibuprofen infusion suitably meets these requirements for short term hospital and emergency department use. Strict regulatory checks assure highest purity, stability and consistent quality of ibuprofen preparations used in pediatric care. These factors, coupled with the non-addictive nature has cemented Ibuprofen infusion as a frontline analgesic in pediatrics inducing higher demand in this segment.

Insights, Distribution Channel: Central Role in Acute Care Drives Hospital Pharmacies Demand

Distribution Channel segment is sub-segmented into hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies segment is expected to hold 39.2% of the market share in 2024 owing to the criticality of pulse oximetry monitoring in acute care settings. Pulse oximetry finds immense utility in hospital departments such as emergency rooms, intensive care units, and operation theatres where constant evaluation of patients' oxygen saturation is imperative. Their non-invasive nature and quick readings ensure minimal disruptions to patient care. Additionally, the larger scale of operations in hospitals translates to higher volumes of pulse oximeter procurement. With oxygen saturation emerging as a vital sign parameter, demand from hospitals continues to accelerate as pulse oximetry becomes further engrained in standard protocols for diverse cases.

Regional Insights

To learn more about this report, request sample copy

North America remains the dominant region in the global intravenous (IV) ibuprofen market and is anticipated to hold 34.8% of the market share in 2024. The strong presence of leading pharmaceutical companies developing and marketing ibuprofen drugs has cemented North America's position. Players like Cumberland Pharmaceuticals, Cadila Healthcare, and XGEN PHARMACEUTICALS DJB, Inc. are long-established in the region and have large market shares with their intravenous (IV) ibuprofen brands. In addition, the availability of generic intravenous (IV) ibuprofen products has made the drug affordable and accessible to a wide population base. This along with supportive regulatory guidelines for pain management has fueled market growth over the years. However, pricing pressures from payers are leading companies to focus on specialty and value-added products.

Asia Pacific region is poised to emerge as the fastest growing market for intravenous (IV) ibuprofen. Countries like India, China, and Japan present immense untapped opportunities due to their burgeoning healthcare industries and large patient pools. Local manufacturers in these countries have ramped up production capacities to serve domestic demand as well as engage in active exporting across Asia Pacific and African countries. Their ability to provide low-cost offerings without compromising on quality provides them a competitive advantage over global established brands. For global players, the Asia Pacific region presents potential for new market expansion through strategic partnerships with regional leaders. Overall, the rapidly increasing healthcare investments, rising per capita incomes, and growing medical tourism are supporting the Asia Pacific intravenous (IV) ibuprofen market to record strong growth over the forecast period.

Market Report Scope

Intravenous (IV) Ibuprofen Industry News

• On February 5, 2024, Hikma Pharmaceuticals PLC, a pharmaceutical company, announced that it had launched COMBOGESIC IV (acetaminophen and ibuprofen) injection in the U.S. COMBOGESIC IV is an intravenous, opioid-free pain relief medicine that is a combination of 1,000 mg of acetaminophen and 300 mg of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID)
• In February 2022, Cumberland Pharmaceuticals Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration had expanded labeling of an intravenously delivered formulation of Caldolor (ibuprofen) Injection to include use in preoperative administration. The expanded approval allows for the use of this nonnarcotic pain reliever to be administered immediately before surgery to enable patients to wake from their procedures in significantly less pain.
• In January 2020, Cumberland Pharmaceuticals Inc., a pharmaceutical company, announced the launch of Caldolor (ibuprofen) Injection in a ready-to-use bag that may be administered without dilution for pain relief

*Definition: Intravenous (IV) ibuprofen market includes products derived from ibuprofen that are administered directly into the bloodstream via intravenous injection or infusion. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used to treat pain and fever. Intravenous (IV) ibuprofen allows for faster absorption and distribution of the drug throughout the body compared to oral ibuprofen tablets or capsules. The intravenous route makes ibuprofen therapy an option

Market Segmentation

•  Indication Insights (Revenue, USD Bn, 2019 - 2031)
  • Pain Management
  • Fever
  • Others
•  Strength Insights (Revenue, USD Bn, 2019 - 2031)
  • 100 mg
  • 200 mg
  • 400 mg
  • 800 mg
•  Age Group Insights (Revenue, USD Bn, 2019 - 2031)
  • Pediatrics
  • Adults
•  Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Cumberland Pharmaceuticals Inc. 
  • Hyloris Pharmaceuticals SA
  • Grifols, S.A.
  • Recordati Rare Diseases Inc.
  • XGEN PHARMACEUTICALS DJB, Inc.
  • AFT Pharmaceuticals
  • Laboratorios Valmorca
  • SGPharma Pvt. Ltd.
  • Wellona Pharma
  • Delex Pharma
  • Hikma Pharmaceuticals PLC